NO2017041I2 - Insulin detemir - Google Patents

Insulin detemir

Info

Publication number: NO2017041I2
Authority: NO; Norway
Prior art keywords: amino acid; acid residue; lys; present; cys
Prior art date: 1993-09-17

Application number

NO2017041C

Other languages

English (en)

Other versions

NO2017041I1 (no

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

2017-08-01

Publication date

2018-11-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-09-17 Priority claimed from DK104493A external-priority patent/DK104493D0/da

2017-08-01 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2017-08-01 Publication of NO2017041I1 publication Critical patent/NO2017041I1/no

2018-11-19 Publication of NO2017041I2 publication Critical patent/NO2017041I2/no

Links

108010089308 Insulin Detemir Proteins 0.000 title 1
229960003948 insulin detemir Drugs 0.000 title 1
UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 title 1
125000000539 amino acid group Chemical group 0.000 abstract 5
125000004432 carbon atom Chemical group C* 0.000 abstract 2
230000002068 genetic effect Effects 0.000 abstract 2
125000002252 acyl group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
150000001735 carboxylic acids Chemical class 0.000 abstract 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
239000004026 insulin derivative Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Toxicology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO2017041C 1993-09-17 2017-08-01 Insulin detemir NO2017041I2 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK104493A DK104493D0 (da)	1993-09-17	1993-09-17	Hidtil ukendte peptider
US19082994A	1994-02-02	1994-02-02
PCT/DK1994/000347 WO1995007931A1 (en)	1993-09-17	1994-09-16	Acylated insulin

Publications (2)

Publication Number	Publication Date
NO2017041I1 NO2017041I1 (no)	2017-08-01
NO2017041I2 true NO2017041I2 (no)	2018-11-19

Family

ID=26065125

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19961070A NO316944B1 (no)	1993-09-17	1996-03-15	Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes
NO2004006C NO2004006I1 (no)	1993-09-17	2004-09-27	Insulin detemir
NO2017041C NO2017041I2 (no)	1993-09-17	2017-08-01	Insulin detemir

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO19961070A NO316944B1 (no)	1993-09-17	1996-03-15	Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes
NO2004006C NO2004006I1 (no)	1993-09-17	2004-09-27	Insulin detemir

Country Status (30)

Country	Link
US (1)	US5750497A (no)
EP (2)	EP0792290B1 (no)
JP (3)	JP3014764B2 (no)
KR (1)	KR100310122B1 (no)
CN (1)	CN1056618C (no)
AT (1)	ATE204882T1 (no)
AU (2)	AU682061B2 (no)
BG (1)	BG61611B1 (no)
BR (1)	BR9407508A (no)
CA (1)	CA2171424C (no)
CZ (1)	CZ287945B6 (no)
DE (2)	DE69428134T2 (no)
DK (1)	DK0792290T3 (no)
ES (1)	ES2163451T3 (no)
FI (1)	FI117055B (no)
FR (1)	FR04C0020I2 (no)
HU (1)	HU217684B (no)
IL (1)	IL110977A (no)
LU (1)	LU91101I2 (no)
NL (1)	NL300160I2 (no)
NO (3)	NO316944B1 (no)
NZ (1)	NZ273285A (no)
PL (1)	PL178466B1 (no)
PT (1)	PT792290E (no)
RO (1)	RO112873B1 (no)
RU (1)	RU2164520C2 (no)
SI (1)	SI0792290T1 (no)
SK (1)	SK282495B6 (no)
UA (1)	UA45321C2 (no)
WO (1)	WO1995007931A1 (no)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9316895D0 (en) *	1993-08-13	1993-09-29	Guy S And St Thomas Hospitals	Hepatoselective insulin analogues
US6342225B1 (en)	1993-08-13	2002-01-29	Deutshces Wollforschungsinstitut	Pharmaceutical active conjugates
US6869930B1 (en) *	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
US5504188A (en) *	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
DE4437604A1 (de) *	1994-10-21	1996-04-25	Basf Ag	Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US5646242A (en) *	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
EP0871665B1 (en) *	1995-03-17	2003-07-23	Novo Nordisk A/S	Insulin derivatives
US6251856B1 (en)	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
US20010041786A1 (en) *	1995-06-07	2001-11-15	Mark L. Brader	Stabilized acylated insulin formulations
GB9513967D0 (en) *	1995-07-08	1995-09-06	Univ Leicester	Insulin
US6451970B1 (en) *	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
DK0921812T4 (da) *	1996-06-20	2012-04-02	Novo Nordisk As	Insulinpræparater, som indeholder et halogenid
AU3255297A (en) *	1996-07-11	1998-02-09	Novo Nordisk A/S	Selective acylation method
US5905140A (en) *	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
DE59711533D1 (de) *	1996-07-26	2004-05-27	Aventis Pharma Gmbh	Insulinderivate mit erhöhter Zinkbindung
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US5898067A (en) *	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
US6310038B1 (en) *	1997-03-20	2001-10-30	Novo Nordisk A/S	Pulmonary insulin crystals
US6043214A (en) *	1997-03-20	2000-03-28	Novo Nordisk A/S	Method for producing powder formulation comprising an insulin
JP3764174B2 (ja) *	1997-03-20	2006-04-05	ノボノルディスクアクティーゼルスカブ	肺用組成物において使用するための亜鉛非含有のインスリン結晶
PL195845B1 (pl) *	1997-10-24	2007-10-31	Novo Nordisk As	Rozpuszczalny w wodzie agregat pochodnych insuliny
US6444641B1 (en)	1997-10-24	2002-09-03	Eli Lilly Company	Fatty acid-acylated insulin analogs
JP2001521004A (ja)	1997-10-24	2001-11-06	イーライ・リリー・アンド・カンパニー	脂肪酸−アシル化インスリン類似体
ZA989644B (en) *	1997-10-24	2000-04-25	Lilly Co Eli	Insoluble insulen compositions.
US6451762B1 (en)	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
ZA989744B (en) *	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
CO4970787A1 (es) *	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (en) *	1997-12-23	2004-03-10	Eli Lilly & Company	Insoluble Insulin Compositions for Controlling Blood Glucose
DE69924232D1 (de) *	1998-01-09	2005-04-21	Novo Nordisk As	Stabilisierte insulin-zubereitungen
JP2002504527A (ja) *	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
DE19825447A1 (de) *	1998-06-06	1999-12-09	Hoechst Marion Roussel De Gmbh	Neue Insulinanaloga mit erhöhter Zinkbildung
EP1086130A1 (en) *	1998-06-12	2001-03-28	Kings College London	Insulin analogue
US7169889B1 (en)	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
DK1265630T3 (da)	2000-03-24	2006-10-09	Genentech Inc	Anvendelse af insulin til behandling af brusksygdomme
JP2003532691A (ja) *	2000-05-05	2003-11-05	ノボノルディスクアクティーゼルスカブ	重症疾患神経障害
US7316999B2 (en)	2000-06-02	2008-01-08	Novo Nordisk A/S	Glucose dependent release of insulin from glucose sensing insulin derivatives
US20030186847A1 (en) *	2000-07-10	2003-10-02	Jones Richard Henry	Insulin derivatives and synthesis thereof
CN1406131A (zh) *	2000-12-25	2003-03-26	株式会社资生堂	活化交感神经的香料组合物
US7060675B2 (en) *	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US6867183B2 (en) *	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6653492B2 (en)	2001-05-02	2003-11-25	Novo Nordick A/S	Preparation of bile acids
ES2271255T3 (es) *	2001-05-02	2007-04-16	Novo Nordisk A/S	Preparacion de acidos biliares.
US6713452B2 (en) *	2001-06-04	2004-03-30	Nobex Corporation	Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) *	2001-06-04	2010-05-11	Biocon Limited	Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) *	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) *	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) *	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP4721212B2 (ja) *	2001-07-05	2011-07-13	株式会社新日本科学	インスリンの経鼻投与用組成物
US7595172B2 (en)	2001-07-24	2009-09-29	Novo Nordisk A/S	Method for making acylated polypeptides
CA2452044A1 (en)	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
EP1430082B1 (en)	2001-09-07	2009-10-28	Biocon Limited	Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) *	2001-09-07	2007-12-25	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) *	2001-09-07	2007-01-23	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) *	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) *	2001-09-07	2005-07-05	Nobex Corporation	Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP2243776A1 (en)	2001-10-12	2010-10-27	High Point Pharmaceuticals, LLC	Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
CA2463803A1 (en)	2001-10-19	2003-05-01	Eli Lilly And Company	Biphasic mixtures of glp-1 and insulin
RU2376379C2 (ru)	2001-11-19	2009-12-20	Ново Нордиск А/С	Способ получения инсулиновых соединений
GB0206792D0 (en)	2002-03-22	2002-05-01	Leuven K U Res & Dev	Normoglycemia
WO2003094956A1 (en) *	2002-05-07	2003-11-20	Novo Nordisk A/S	Soluble formulations comprising monomeric insulin and acylated insulin
AU2003236521A1 (en)	2002-06-13	2003-12-31	Nobex Corporation	Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040038864A1 (en) *	2002-06-27	2004-02-26	Per Balschmidt	Use of dimethyl sulfone as isotonicity agent
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
DE60328112D1 (de) *	2002-09-25	2009-08-06	Novo Nordisk As	Verfahren zur herstellung acylierter peptide
WO2004035624A2 (en)	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
US20040138099A1 (en) *	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (en) *	2003-03-27	2004-10-07	Novo Nordisk A/S	Method for making human insulin precursors and human insulin
ATE482747T1 (de)	2003-04-11	2010-10-15	High Point Pharmaceuticals Llc	Neue amide derivate und deren pharmazeutische verwendungen
WO2004096266A1 (en) *	2003-05-02	2004-11-11	Novo Nordisk A/S	Improved physical stability of insulin formulations
JP4781264B2 (ja)	2003-06-27	2011-09-28	ノボ・ノルデイスク・エー／エス	医療用液体組成物の高水分遮断容器
EP2107069B1 (en) *	2003-08-05	2013-01-16	Novo Nordisk A/S	Novel insulin derivatives
ES2472421T3 (es)	2003-08-05	2014-07-01	Novo Nordisk A/S	Nuevos derivados de insulina
EP1687428A1 (en)	2003-11-14	2006-08-09	Novo Nordisk A/S	Processes for making acylated insulin
PT1687019T (pt)	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
JP5697831B2 (ja)	2003-12-03	2015-04-08	ノヴォノルディスクアー／エス	単鎖インシュリン
CN1898087A (zh)	2003-12-22	2007-01-17	诺沃挪第克公司	用于储存药物液体的透明、柔性、不可渗透的塑料容器
ES2642214T3 (es)	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
PL2319500T3 (pl) *	2004-03-12	2013-05-31	Biodel Inc	Szybko działające kompozycje do dostarczania leku
WO2006008238A1 (en) *	2004-07-16	2006-01-26	Novo Nordisk A/S	Method for selective acylation
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
ES2438145T3 (es)	2005-02-02	2014-01-16	Novo Nordisk A/S	Nuevos derivados de insulina
JP5410020B2 (ja) *	2005-02-02	2014-02-05	ノヴォノルディスクアー／エス	インスリン誘導体
WO2006125763A1 (en)	2005-05-25	2006-11-30	Novo Nordisk A/S	Stabilized polypeptide formulations
US20090060861A1 (en) *	2005-05-25	2009-03-05	Novo Nordisk A/S	Stabilized Polypeptide Formulations
WO2006125765A2 (en) *	2005-05-26	2006-11-30	Novo Nordisk A/S	Acylated insulin with high purity
EP2386554A1 (en)	2005-07-04	2011-11-16	High Point Pharmaceuticals, LLC	Compounds active at the histamine H3 receptor
US8106090B2 (en)	2005-07-20	2012-01-31	Eli Lilly And Company	1-amino linked compounds
CN102660614A (zh)	2005-08-16	2012-09-12	诺沃-诺迪斯克有限公司	制备成熟胰岛素多肽的方法
US7741281B2 (en) *	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
DK1951658T3 (da)	2005-11-17	2012-10-15	Lilly Co Eli	Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
AU2007207618B2 (en) *	2006-01-18	2011-03-24	Foresee Pharmaceuticals Co., Ltd.	Pharmaceutical compositions with enhanced stability
JP5202338B2 (ja)	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	新規インシュリン誘導体
US20090069215A1 (en) *	2006-03-13	2009-03-12	Novo Nordisk A/S	Acylated Single Chain Insulin
US20090054305A1 (en)	2006-03-15	2009-02-26	Novo Nordisk A/S	Mixtures of Amylin and Insulin
US8394842B2 (en)	2006-03-28	2013-03-12	High Point Pharmaceuticals, Llc	Benzothiazoles having histamine H3 receptor activity
EA016415B1 (ru)	2006-04-24	2012-04-30	Эли Лилли Энд Компани	Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
BRPI0712041A2 (pt) *	2006-05-09	2011-12-27	Novo Nordisk As	derivado de insulina
CN101437849B (zh) *	2006-05-09	2015-09-30	诺沃-诺迪斯克有限公司	胰岛素衍生物
US8796205B2 (en)	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
US7714025B2 (en) *	2006-05-10	2010-05-11	Arizona Biomedical Research Commission	Modified chalcone compounds as antimitotic agents
EP2079732B9 (en)	2006-05-29	2012-03-21	High Point Pharmaceuticals, LLC	3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
RU2456018C2 (ru)	2006-07-11	2012-07-20	КьюПиЭс, ЭлЭлСи	Фармацевтические композиции для доставки пептидов с замедленным высвобождением
JP5550338B2 (ja)	2006-07-31	2014-07-16	ノボ・ノルデイスク・エー／エス	ペグ化持続型インスリン
HUE029512T2 (en)	2006-09-22	2017-03-28	Novo Nordisk As	Protease Resistant Insulin Analogs
US8518668B2 (en)	2006-09-27	2013-08-27	Novo Nordisk A/S	Method for making maturated insulin polypeptides in a fungal cell
WO2008049711A1 (en) *	2006-10-27	2008-05-02	Novo Nordisk A/S	Peptide extended insulins
JP5496082B2 (ja)	2007-04-30	2014-05-21	ノボ・ノルデイスク・エー／エス	タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US20100190706A1 (en)	2007-06-01	2010-07-29	Novo Nordisk A/S	Stable Non-Aqueous Pharmaceutical Compositions
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
CN101778862B (zh)	2007-08-13	2014-12-17	诺沃-诺迪斯克有限公司	快速作用的胰岛素类似物
US9241908B2 (en) *	2007-10-16	2016-01-26	Biocon Limited	Orally administrable solid pharmaceutical composition and a process thereof
EP2058330A1 (en) *	2007-11-08	2009-05-13	Novo Nordisk A/S	Insulin derivative
US8710000B2 (en)	2007-11-08	2014-04-29	Novo Nordisk A/S	Insulin derivative
WO2009063072A2 (en)	2007-11-16	2009-05-22	Novo Nordisk A/S	Pharmaceutical compositions containing insulin and an insulinotropic peptide
US20090175840A1 (en) *	2008-01-04	2009-07-09	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
JP5762001B2 (ja)	2008-03-14	2015-08-12	ノボ・ノルデイスク・エー／エス	プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en)	2008-03-18	2009-09-24	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
KR20110059602A (ko)	2008-08-07	2011-06-02	바이오콘 리미티드	인슐린 화합물의 제조방법
KR20110085985A (ko)	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
MX2011005037A (es)	2008-11-21	2011-06-16	High Point Pharmaceuticals Llc	Compuestos de adamantilo benzamida.
WO2010088286A1 (en)	2009-01-28	2010-08-05	Smartcells, Inc.	Synthetic conjugates and uses thereof
BRPI1007457A2 (pt) *	2009-01-28	2015-08-25	Smartcells Inc	Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
CA2754950A1 (en)	2009-03-20	2010-09-23	Smartcells, Inc.	Terminally-functionalized conjugates and uses thereof
WO2010140148A1 (en)	2009-06-01	2010-12-09	Yeda Research And Development Co . Ltd	Prodrugs containing albumin binding probe
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
EP2359843A1 (en)	2010-01-21	2011-08-24	Sanofi	Pharmaceutical composition for treating a metabolic syndrome
US9981017B2 (en)	2010-04-02	2018-05-29	Hanmi Science Co., Ltd.	Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es)	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	Conjugado de insulina donde se usa un fragmento de inmunoglobulina
UY33326A (es)	2010-04-14	2011-12-01	Sanofi Aventis	Conjugados de insulina-sirna
JP6249773B2 (ja) *	2010-05-10	2017-12-20	ノヴォノルディスクアー／エス	インスリン−亜鉛錯体の調製方法
WO2012049307A2 (en) *	2010-10-15	2012-04-19	Novo Nordisk A/S	Novel n-terminally modified insulin derivatives
BR112013010345A2 (pt)	2010-10-27	2017-07-25	Novo Nordisk As	tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
PL2654794T3 (pl)	2010-12-22	2020-07-27	Baxalta GmbH	Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
SG192038A1 (en)	2011-01-20	2013-08-30	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
EP2670368A4 (en)	2011-02-03	2015-04-15	Pharmedica Ltd	NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
US9480751B2 (en)	2011-04-11	2016-11-01	Yeda Research And Development Co. Ltd.	Albumin binding probes and drug conjugates thereof
EP2548570A1 (en)	2011-07-19	2013-01-23	Sanofi	Pharmaceutical composition for treating a metabolic syndrome
CN102504022A (zh) *	2011-11-30	2012-06-20	苏州元基生物技术有限公司	含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
RU2014127270A (ru) *	2011-12-15	2016-02-10	Шанхай Хэнжуй Фармасьютикал Ко., Лтд.	Аналог человеческого инсулина и его ацилированное производное
CA2870313A1 (en)	2012-04-11	2013-10-17	Novo Nordisk A/S	Insulin formulations
EP2844274B1 (en)	2012-05-01	2019-03-20	Novo Nordisk A/S	Pharmaceutical composition
US9707276B2 (en)	2012-12-03	2017-07-18	Merck Sharp & Dohme Corp.	O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
AU2014318579A1 (en)	2013-09-13	2016-04-14	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
KR102455171B1 (ko)	2013-12-18	2022-10-14	더 스크립스 리서치 인스티튜트	변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
AR099569A1 (es)	2014-02-28	2016-08-03	Novo Nordisk As	Derivados de insulina y los usos médicos de estos
WO2015196174A1 (en)	2014-06-20	2015-12-23	Greene Howard E	Infusion delivery devices and methods
WO2016205488A1 (en)	2015-06-17	2016-12-22	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
AR106364A1 (es)	2015-08-25	2018-01-10	Novo Nordisk As	Derivados de insulina y sus usos médicos
WO2018024186A1 (zh) *	2016-08-02	2018-02-08	江苏恒瑞医药股份有限公司	一种人胰岛素或其类似物的酰化衍生物
EP3329930A1 (en)	2016-12-05	2018-06-06	Nuritas Limited	Pharmaceuctical compositions
KR20240128130A (ko)	2016-12-05	2024-08-23	뉴리타스 리미티드	펩티드 wkdeagkplvk를 포함하는 조성물
ES2886837T3 (es)	2016-12-16	2021-12-21	Novo Nordisk As	Composiciones farmacéuticas que contienen insulina
HUE066356T2 (hu)	2017-08-24	2024-07-28	Novo Nordisk As	GLP-1 készítmények és alkalmazásaik
JP2020535199A (ja) *	2017-09-29	2020-12-03	ハンミファーマシューティカルカンパニーリミテッド	効力が向上した持続性タンパク質結合体
WO2019125879A2 (en)	2017-12-18	2019-06-27	Merck Sharp & Dohme Corp.	Conjugate based systems for controlled insulin delivery
EP3727424A4 (en)	2017-12-18	2021-10-27	Merck Sharp & Dohme Corp.	CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
US20210032307A1 (en)	2018-02-09	2021-02-04	Jiangsu Hengrui Medicine Co., Ltd.	Codon optimized precursor gene and signal peptide gene of human insulin analogue
JP2021524464A (ja)	2018-05-24	2021-09-13	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司ＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	組換えヒトインスリンまたはそのアナログの前駆体の調製方法
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR102666154B1 (ko)	2018-08-08	2024-05-20	주식회사 대웅제약	지속형 인슐린 아날로그 및 그 복합체
WO2020120477A1 (en)	2018-12-11	2020-06-18	Sanofi	Insulin analogs having reduced insulin receptor binding affinity
KR20200080747A (ko)	2018-12-27	2020-07-07	주식회사 폴루스	인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko)	2018-12-27	2020-07-07	주식회사 폴루스	음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
CN111909255A (zh) *	2019-05-10	2020-11-10	宁波鲲鹏生物科技有限公司	胰岛素衍生物及其制备方法
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
TW202434620A (zh)	2019-07-31	2024-09-01	美商美國禮來大藥廠	鬆弛素(relaxin)類似物及其使用方法
CA3163507A1 (en)	2019-12-04	2021-06-10	The Scripps Research Institute	Peptide conjugates and methods of use
DK4073097T3 (da)	2019-12-11	2024-08-19	Novo Nordisk As	Nye insulinanaloger og anvendelser heraf
CN118420744A (zh)	2019-12-30	2024-08-02	甘李药业股份有限公司	胰岛素衍生物
AU2020418207A1 (en)	2019-12-30	2022-08-25	Gan & Lee Pharmaceuticals Co., Ltd.	Long-acting GLP-1 compound
PE20221575A1 (es)	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas
CA3173417A1 (en)	2020-03-31	2021-10-07	Alborz Mahdavi	Conjugates for selective responsiveness to vicinal diols
PH12023500012A1 (en)	2020-11-19	2024-03-11	Protomer Tech Inc	Aromatic boron-containing compounds and insulin analogs
IL309067A (en)	2021-06-09	2024-02-01	Scripps Research Inst	Long-acting dual gip/glp-1 peptide conjugates and methods of use
EP4299057A1 (en)	2022-06-30	2024-01-03	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en)	2021-11-15	2025-01-02	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en)	2021-11-15	2023-05-17	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250340610A1 (en)	2022-01-28	2025-11-06	Gan & Lee Pharmaceuticals Co., Ltd.	Acylated insulin
EP4299071A1 (en)	2022-07-01	2024-01-03	Adocia	Compositions comprising a peptide or a protein and an acylated amino acid
WO2024051787A1 (zh) *	2022-09-09	2024-03-14	北京惠之衡生物科技有限公司	一种长效酰化胰岛素衍生物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3823125A (en) *	1969-10-14	1974-07-09	American Home Prod	N-aminoacyl-substituted insulins
US3950517A (en) *	1970-05-08	1976-04-13	National Research Development Corporation	Insulin derivatives
GB1381273A (en) *	1971-01-28	1975-01-22	Nat Res Dev	Insulin derivatives
GB1381274A (en) *	1971-01-28	1975-01-22	Nat Res Dev	Insulin derivatives
US3907763A (en) *	1972-03-01	1975-09-23	Bayer Ag	Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) *	1980-07-24	1982-01-25	Forenede Bryggerier As	Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
NL8201650A (nl) *	1982-04-21	1983-11-16	Akzo Nv	Semisynthetische bereiding van humane insuline.
IL68769A (en) *	1983-05-23	1986-02-28	Hadassah Med Org	Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
JPH01254699A (ja) *	1988-04-05	1989-10-11	Kodama Kk	インスリン誘導体及びその用途
DK45590D0 (no) *	1990-02-21	1990-02-21	Novo Nordisk As
DK155690D0 (da) *	1990-06-28	1990-06-28	Novo Nordisk As	Nye peptider
WO1992001476A1 (en) *	1990-07-26	1992-02-06	University Of Iowa Research Foundation	Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) *	1991-04-24	1994-08-09	Kuraray Co., Ltd.	Long chain carboxylic acid imide ester

1994
- 1994-09-16 SI SI9430396T patent/SI0792290T1/xx unknown
- 1994-09-16 DE DE69428134T patent/DE69428134T2/de not_active Expired - Lifetime
- 1994-09-16 DK DK94926816T patent/DK0792290T3/da active
- 1994-09-16 EP EP94926816A patent/EP0792290B1/en not_active Expired - Lifetime
- 1994-09-16 DE DE122004000035C patent/DE122004000035I2/de active Active
- 1994-09-16 CA CA002171424A patent/CA2171424C/en not_active Expired - Lifetime
- 1994-09-16 CN CN94193852A patent/CN1056618C/zh not_active Expired - Lifetime
- 1994-09-16 CZ CZ1996789A patent/CZ287945B6/cs not_active IP Right Cessation
- 1994-09-16 KR KR1019960701400A patent/KR100310122B1/ko not_active Expired - Lifetime
- 1994-09-16 UA UA96030967A patent/UA45321C2/uk unknown
- 1994-09-16 EP EP01112992A patent/EP1132404A3/en not_active Withdrawn
- 1994-09-16 NZ NZ273285A patent/NZ273285A/en not_active IP Right Cessation
- 1994-09-16 ES ES94926816T patent/ES2163451T3/es not_active Expired - Lifetime
- 1994-09-16 PL PL94313444A patent/PL178466B1/pl unknown
- 1994-09-16 PT PT94926816T patent/PT792290E/pt unknown
- 1994-09-16 RO RO96-00583A patent/RO112873B1/ro unknown
- 1994-09-16 SK SK324-96A patent/SK282495B6/sk active Protection Beyond IP Right Term
- 1994-09-16 AU AU76520/94A patent/AU682061B2/en not_active Expired
- 1994-09-16 JP JP7508923A patent/JP3014764B2/ja not_active Expired - Lifetime
- 1994-09-16 HU HU9600676A patent/HU217684B/hu active Protection Beyond IP Right Term
- 1994-09-16 RU RU96108249/04A patent/RU2164520C2/ru active Protection Beyond IP Right Term
- 1994-09-16 WO PCT/DK1994/000347 patent/WO1995007931A1/en not_active Ceased
- 1994-09-16 AT AT94926816T patent/ATE204882T1/de active
- 1994-09-16 BR BR9407508A patent/BR9407508A/pt not_active Application Discontinuation
- 1994-09-16 IL IL11097794A patent/IL110977A/xx active Protection Beyond IP Right Term
1995
- 1995-03-08 US US08/400,256 patent/US5750497A/en not_active Expired - Lifetime
1996
- 1996-03-13 BG BG100420A patent/BG61611B1/bg unknown
- 1996-03-15 FI FI961220A patent/FI117055B/fi active Protection Beyond IP Right Term
- 1996-03-15 NO NO19961070A patent/NO316944B1/no not_active IP Right Cessation
1997
- 1997-12-18 AU AU48461/97A patent/AU4846197A/en not_active Abandoned
1999
- 1999-08-04 JP JP22163299A patent/JP3917333B2/ja not_active Expired - Lifetime
2001
- 2001-12-19 JP JP2001385921A patent/JP4060583B2/ja not_active Expired - Lifetime
2004
- 2004-09-06 FR FR04C0020C patent/FR04C0020I2/fr active Active
- 2004-09-08 LU LU91101C patent/LU91101I2/xx unknown
- 2004-09-24 NL NL300160C patent/NL300160I2/nl unknown
- 2004-09-27 NO NO2004006C patent/NO2004006I1/no unknown
2017
- 2017-08-01 NO NO2017041C patent/NO2017041I2/no unknown

Also Published As

Publication number	Publication date
FI961220L (fi)	1996-05-14
JP3917333B2 (ja)	2007-05-23
PL178466B1 (pl)	2000-05-31
DK0792290T3 (da)	2001-10-01
EP1132404A3 (en)	2002-03-27
LU91101I2 (en)	2004-11-08
NO2004006I1 (no)	2004-10-11
JPH09502867A (ja)	1997-03-25
KR100310122B1 (ko)	2002-04-24
US5750497A (en)	1998-05-12
AU682061B2 (en)	1997-09-18
CA2171424C (en)	2002-06-04
NO961070D0 (no)	1996-03-15
NO2017041I1 (no)	2017-08-01
AU7652094A (en)	1995-04-03
SK32496A3 (en)	1996-11-06
DE122004000035I2 (de)	2009-08-06
JP2000060556A (ja)	2000-02-29
IL110977A0 (en)	1994-11-28
CN1133598A (zh)	1996-10-16
FI961220A0 (fi)	1996-03-15
DE69428134D1 (de)	2001-10-04
BG61611B1 (bg)	1998-01-30
AU4846197A (en)	1998-02-19
WO1995007931A1 (en)	1995-03-23
FI117055B (fi)	2006-05-31
NL300160I1 (nl)	2004-12-01
EP1132404A2 (en)	2001-09-12
ATE204882T1 (de)	2001-09-15
BR9407508A (pt)	1997-01-07
DE69428134T2 (de)	2002-05-02
KR960704925A (ko)	1996-10-09
NO961070L (no)	1996-05-15
CZ78996A3 (en)	1996-10-16
SI0792290T1 (en)	2001-12-31
PL313444A1 (en)	1996-07-08
CN1056618C (zh)	2000-09-20
ES2163451T3 (es)	2002-02-01
NO2004006I2 (no)	2008-02-04
RO112873B1 (ro)	1998-01-30
NL300160I2 (nl)	2005-07-01
BG100420A (bg)	1996-12-31
CA2171424A1 (en)	1995-03-23
JP3014764B2 (ja)	2000-02-28
HU217684B (hu)	2000-03-28
FR04C0020I2 (fr)	2005-05-27
JP4060583B2 (ja)	2008-03-12
NZ273285A (en)	1997-10-24
RU2164520C2 (ru)	2001-03-27
HUT75991A (en)	1997-05-28
HU9600676D0 (en)	1996-05-28
EP0792290B1 (en)	2001-08-29
CZ287945B6 (cs)	2001-03-14
IL110977A (en)	2000-06-29
DE122004000035I1 (de)	2005-02-24
SK282495B6 (sk)	2002-02-05
JP2002308899A (ja)	2002-10-23
FR04C0020I1 (no)	2004-10-29
UA45321C2 (uk)	2002-04-15
PT792290E (pt)	2002-01-30
EP0792290A1 (en)	1997-09-03
NO316944B1 (no)	2004-07-05

Publication	Publication Date	Title
NO2004006I1 (no)	2004-10-11	Insulin detemir
RU96108249A (ru)	1998-07-20	Ацилированный инсулин
NZ330700A (en)	1999-11-29	B27, B28, B29 (B chain) insulin derivatives having a rapid onset of action
KR920701250A (ko)	1992-08-11	신규 인슐린 화합물
KR870002165A (ko)	1987-03-30	인슈린유사체 및 그의 제조방법
EP0254516A3 (en)	1990-06-27	Novel peptides
NO912438D0 (no)	1991-06-21	Humaninsulinanaloger.
ZA971510B (en)	1997-09-22	Peptide derivatives.
KR900002801A (ko)	1990-03-23	당뇨병 치료용 약학적제제
DE69629210D1 (de)	2003-08-28	Insulinabkömmlinge
CA2081659A1 (en)	1992-09-16	Recombinant human factor viii derivatives
CA2385857A1 (en)	2001-04-12	C peptide for improved preparation of insulin and insulin analogs
CA2087450A1 (en)	1992-01-17	Stable and bioactive modified somatotropins
SE9101586D0 (sv)	1991-05-24	Modified thioredoxin and its use
DK119391A (da)	1991-08-22	Humaninsulinanaloger